Beeline’s Afimetoran Meets Phase 2 Endpoint in SLE

Written By: Kirti Kumbhar, M. Pharm (QA)

Reviewed By: Pharmacally Editorial Team

Beeline Medicines’ oral TLR7/8 inhibitor afimetoran produced significantly higher SRI-4 response rates than placebo at Week 48 in a 248-patient Phase 2 systemic lupus erythematosus study, with all three dose groups meeting the primary endpoint.

Beeline Medicines has reported positive topline Phase 2 results for afimetoran, an investigational once-daily oral inhibitor of Toll-like receptors 7 and 8 (TLR7/8), in adults with active moderate-to-severe systemic lupus erythematosus (SLE).

The global trial met its primary endpoint, with all three afimetoran dose groups showing higher SLE Responder Index-4 (SRI-4) response rates than placebo at Week 48. Each dose group achieved a p-value below 0.001. Secondary endpoints also showed improvements consistent with the primary outcome, supporting further development of the therapy.

TLR7/8 inhibition targets a central lupus pathway

Afimetoran selectively inhibits TLR7 and TLR8, innate immune receptors involved in lupus pathogenesis. Human genetic evidence directly implicates TLR7 as a disease driver, while TLR8 contributes to inflammatory cytokine production and immune responses.

Blocking TLR7/8 signaling suppresses pathways in innate immune cells and B cells that contribute to autoimmune inflammation and disease activity. The mechanism could therefore address both systemic and cutaneous manifestations of lupus.

SLE can affect multiple organ systems and follow a relapsing course in which recurrent inflammatory flares contribute to irreversible organ damage. Despite recent treatment advances, patients still need effective oral targeted therapies that can provide durable disease control while limiting corticosteroid exposure.

Phase 2 enrolled 248 adults with active SLE

The Phase 2 study (NCT04895696) was a global, double-blind, randomized, dose-ranging, placebo-controlled trial involving 248 adults aged 18 to 70 years with active moderate-to-severe SLE despite ongoing background treatment.

Participants were randomized 1:1:1:1 to receive once-daily oral afimetoran at one of three dose levels or placebo through Week 48. Treatment was given alongside protocol-permitted standard-of-care medications, including corticosteroids with a mandatory taper.

The primary endpoint was SRI-4 response at Week 48. All three afimetoran dose groups achieved statistically significant improvements versus placebo, with p<0.001 across each dose group.

Secondary endpoints assessed several clinically relevant measures, including low disease activity, skin and joint manifestations, corticosteroid reduction, physician global assessment and quality of life. Beeline reported improvements across these measures consistent with the primary endpoint, although the topline release did not disclose the underlying numerical results.

Safety profile remains consistent with Phase 1

Afimetoran was generally well tolerated in the Phase 2 study. The safety profile remained consistent with previous Phase 1 clinical experience, and no new safety signals were observed.

The detailed safety dataset will be important as the program moves toward pivotal development, particularly given the need to establish the benefit-risk profile of long-term TLR7/8 inhibition in a larger patient population.

Pivotal development planned in SLE and CLE

Beeline plans to advance afimetoran into pivotal development for both SLE and cutaneous lupus erythematosus (CLE).

The company previously reported exploratory efficacy with afimetoran in a Phase 1b CLE study. The FDA granted the therapy Fast Track designation for SLE in May 2025. Beeline licensed afimetoran from Bristol Myers Squibb in July 2025, following its discovery by BMS researchers.

Detailed Phase 2 results are expected at an upcoming medical congress. The presentation should provide the numerical SRI-4 response rates by dose and additional data from the secondary endpoints, including corticosteroid reduction and skin and joint outcomes.

For investors and clinicians, the next major milestone will be the definition of the pivotal development program, including study design, patient populations, endpoints and dosing strategy. If the full dataset confirms the topline findings, afimetoran could advance as an oral targeted approach for both systemic and cutaneous lupus.

Reference

Beeline Medicines Announces Positive Topline Results from Global Phase 2 Study of Afimetoran in Systemic Lupus Erythematosus, Beeline Medicine, 09 September 2026